Alethio Therapeutics
A spin-out from the University of Oxford, Alethio Therapeutics is pioneering the development of targeted therapies with disease-modifying potential for patients with blood cancers, with the aim of helping them live fully, freely and well. The Company is focused on myeloproliferative neoplasms (MPNs), a group of chronic, incurable blood cancers where currently approved treatments are not selectively targeting disease-driving cells.
Sector
Biopharmaceuticals
Strategy
Status
Live
Website
www.alethiotherapeutics.com
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.